BioSpace News Archive

Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its fourth quarter and fiscal year-end 2020 financial results on Tuesday, July 21, 2020 after the close of trading.

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the year ended March 31, 2020.

Bien-Etre Labs, LLC, a nutraceutical development company designing pre- and probiotic supplements to regulate the human biome, as well as researching novel approaches to healthy ageing and longevity, announces the appointment of Mr. Steve P. Prescott to the position of President of the company.

However, high levels of mask wearing could reduce forecasted deaths by nearly 33,060 Next two weeks will show whether surge in deaths follows increase in cases

Leaders of the American Association of Nurse Anesthetists are encouraged by the Centers for Medicare & Medicaid Services announcement on the creation of the Office of Burden Reduction and Health Informatics in an effort to “cut red tape” for providers.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure (NASDAQ: QURE), a leading gene therapy company.

Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, at a public offering price of $3.75 per share, before underwriting discounts and commissions.

Singapore-based biotech company TurtleTree Labs today announced the completion of a fresh round of funding from global investors. TurtleTree Labs is the world’s first-cell based biotechnology company creating real milk from mammalian cells, without the need for animals

Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $37.00 per share.